India joined Abbott Laboratories Inc.’s global viral surveillance efforts last year and Gavin Cloherty, the US company’s head of infectious disease research, highlighted how things are shaping in its alliance in the area with YRG CARE, a leading institution for HIV/AIDS research in India.
Abbott’s Cloherty On Viral Surveillance And Evolving Viruses
Gavin Cloherty, Abbott’s head of infectious disease research, tells Scrip how the company’s global viral surveillance program helps it stay ahead of HIV and hepatitis evolution, outlines efforts at a partnership in India on viral diversity to help improve diagnostic accuracy and shares new findings from the company’s virus discovery program.
More from R&D
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
More from Scrip
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.
• By
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.